Dudreuilh, C
Jarvis, P
Beadle, N
Pilecka, I
Shaw, O
Gardner, L
Scottà, C
Mamode, N
Game, DS
Sanchez-Fueyo, A
Lombardi, G
Learoyd, A
Douiri, A
Dorling, A
Funding for this research was provided by:
Medical Research Council (MR/S000852/1, (Award number MR/T025573/1))
Article History
Received: 8 November 2022
Accepted: 6 April 2023
First Online: 28 April 2023
Declarations
:
: The trial will be conducted in compliance with the principles of the Declaration of Helsinki (1996), the principles of Good Clinical Practice and in accordance with all applicable regulatory requirements including but not limited to the Research Governance Framework and the Medicines for Human Use (Clinical Trial) Regulations 2004, as amended in 2006 and any subsequent amendments. This protocol and related documents have been approved by the South Central – Oxford A Research Ethics Committee (REC ref number: 21/SC/0253) and authorised by the Medicines and Healthcare products Regulatory Agency. Patients will be asked to provide written 'informed' consent to inclusion in both Part 1 and Part 2 of the study.
: Not applicable.
: The authors declare no competing interests.